Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have an established diagnosis of UC for ≥3 months
Have confirmed diagnosis of moderately for severely active UC
Have current bowel urgency
Have demonstrated an inadequate response to, a loss of response to, or an intolerance to conventional or to biologic/Janus Kinase (JAK) inhibitor/sphingosine-1-phosphate (S1P) receptor modulator therapy for UC.
You may not be if
Have Crohn's disease (CD)
Have inflammatory bowel disease-unclassified, formerly known as indeterminate colitis, or
Have ulcerative proctitis, disease limited to the rectum, that is, distal to the recto-sigmoid junction, which lies approximately 10 to 15 centimeter (cm) from anal verge.
Have an inherited immunodeficiency syndrome or a monogenic cause of UC-like colonic inflammation
Have any history or current evidence of cancer of the gastrointestinal tract
Have active tuberculosis
Have HIV infection.
Clareo Health | A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis
